See more : Tower One Wireless Corp. (TOWTF) Income Statement Analysis – Financial Results
Complete financial analysis of SSY Group Limited (LJUIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SSY Group Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Viscom AG (V6C.DE) Income Statement Analysis – Financial Results
- NCT Alliance Berhad (0056.KL) Income Statement Analysis – Financial Results
- Fujii Sangyo Corporation (9906.T) Income Statement Analysis – Financial Results
- Computershare Limited (CMSQY) Income Statement Analysis – Financial Results
- Bright Real Estate Group Co.,Limited (600708.SS) Income Statement Analysis – Financial Results
SSY Group Limited (LJUIF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ssygroup.com.hk
About SSY Group Limited
SSY Group Limited, an investment holding company, researches, develops, manufactures, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; and food, beverages, and catering business. It sells its products under Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was incorporated in 2004 and is headquartered in Wanchai, Hong Kong. SSY Group Limited is a subsidiary of China Pharmaceutical Co., Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.46B | 6.43B | 5.36B | 4.26B | 4.64B | 4.18B | 3.08B | 2.36B | 2.22B | 2.09B | 2.75B | 2.43B | 2.16B | 1.97B | 1.74B | 1.59B | 1.18B | 858.32M | 849.92M | 847.58M |
| Cost of Revenue | 2.84B | 2.99B | 2.32B | 1.68B | 1.84B | 1.57B | 1.27B | 1.14B | 1.17B | 1.03B | 1.51B | 1.40B | 1.24B | 980.03M | 880.26M | 863.50M | 581.13M | 414.69M | 419.66M | 421.74M |
| Gross Profit | 3.62B | 3.44B | 3.04B | 2.58B | 2.79B | 2.61B | 1.81B | 1.22B | 1.05B | 1.07B | 1.23B | 1.03B | 913.69M | 991.63M | 859.36M | 727.53M | 599.32M | 443.64M | 430.25M | 425.84M |
| Gross Profit Ratio | 56.01% | 53.46% | 56.71% | 60.57% | 60.26% | 62.34% | 58.74% | 51.56% | 47.24% | 50.94% | 44.89% | 42.50% | 42.39% | 50.29% | 49.40% | 45.73% | 50.77% | 51.69% | 50.62% | 50.24% |
| Research & Development | 289.75M | 226.35M | 208.77M | 75.68M | 75.35M | 46.80M | 58.13M | 41.38M | 38.20M | 37.51M | 25.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 91.03M | 284.83M | 281.78M | 281.34M | 378.93M | 336.26M | 306.20M | 241.75M | 277.99M | 217.48M | 291.53M | 290.20M | 466.78M | 215.43M | 599.99M | 610.91M | 156.21M | 346.78M | 298.97M | 297.81M |
| Selling & Marketing | 1.44B | 1.66B | 1.71B | 1.61B | 1.26B | 1.23B | 656.09M | 373.16M | 280.52M | 262.72M | 497.71M | 410.80M | 441.34M | 461.27M | 0.00 | 0.00 | 301.22M | 0.00 | 0.00 | 0.00 |
| SG&A | 1.53B | 1.85B | 1.93B | 1.82B | 1.48B | 1.57B | 962.28M | 614.91M | 558.51M | 484.37M | 789.24M | 701.00M | 908.13M | 676.70M | 599.99M | 610.91M | 457.43M | 346.78M | 298.97M | 297.81M |
| Other Expenses | 161.33M | 6.14M | 11.43M | 7.06M | 8.81M | 0.00 | 0.00 | 64.07M | 0.00 | 0.00 | -93.42M | -38.05M | -7.58M | -10.07M | -21.40M | 0.00 | 0.00 | -4.88M | -6.79M | -6.67M |
| Operating Expenses | 1.98B | 2.08B | 2.13B | 1.89B | 1.55B | 1.49B | 957.26M | 582.16M | 531.67M | 444.42M | 695.82M | 662.95M | 900.54M | 666.63M | 578.58M | 610.91M | 457.43M | 346.78M | 298.97M | 297.81M |
| Cost & Expenses | 4.82B | 5.08B | 4.45B | 3.57B | 3.39B | 3.06B | 2.23B | 1.73B | 1.70B | 1.47B | 2.21B | 2.06B | 2.14B | 1.65B | 1.46B | 1.47B | 1.04B | 761.47M | 718.63M | 719.55M |
| Interest Income | 33.92M | 29.20M | 24.71M | 22.98M | 23.37M | 37.56M | 52.55M | 47.36M | 39.58M | 40.83M | 1.56M | 1.24M | 2.77M | 4.54M | 1.33M | 2.10M | 4.07M | 5.20M | 0.00 | 0.00 |
| Interest Expense | 125.41M | 90.91M | 65.63M | 64.86M | 69.09M | 53.15M | 56.63M | 56.69M | 60.83M | 44.74M | 50.68M | 32.89M | 18.11M | 23.85M | 41.11M | 41.22M | 34.44M | 4.88M | 6.79M | 6.67M |
| Depreciation & Amortization | 405.57M | 371.06M | 389.81M | 317.36M | 276.35M | 276.18M | 256.51M | 241.01M | 210.30M | 156.31M | 145.30M | 151.54M | 120.75M | 103.58M | 95.44M | 87.19M | 4.07M | -175.53K | -2.00M | -1.97M |
| EBITDA | 2.11B | 1.86B | 1.40B | 1.09B | 1.69B | 1.38B | 1.11B | 906.14M | 750.76M | 785.38M | 689.46M | 522.18M | 140.63M | 434.33M | 377.35M | 221.70M | 171.20M | 129.81M | 131.29M | 128.03M |
| EBITDA Ratio | 32.72% | 26.88% | 24.15% | 23.58% | 32.77% | 33.13% | 35.86% | 38.38% | 33.79% | 37.00% | 25.03% | 21.35% | 6.34% | 21.97% | 21.70% | 13.93% | 14.50% | 11.28% | 15.45% | 15.11% |
| Operating Income | 1.64B | 1.36B | 903.79M | 687.17M | 1.24B | 1.11B | 852.99M | 666.60M | 540.45M | 617.44M | 538.83M | 372.22M | 13.15M | 324.99M | 280.78M | 132.40M | 167.12M | 97.03M | 133.28M | 130.00M |
| Operating Income Ratio | 25.36% | 21.11% | 16.87% | 16.13% | 26.81% | 26.52% | 27.73% | 28.23% | 24.32% | 29.52% | 19.63% | 15.31% | 0.61% | 16.48% | 16.14% | 8.32% | 14.16% | 11.30% | 15.68% | 15.34% |
| Total Other Income/Expenses | -55.33M | -24.56M | -39.69M | -33.67M | -30.51M | -34.31M | -53.93M | -52.61M | -63.23M | -41.35M | -31.69M | -35.71M | -15.34M | -19.31M | -39.78M | -39.12M | -29.32M | -4.88M | -5.28M | -6.67M |
| Income Before Tax | 1.58B | 1.40B | 948.40M | 725.22M | 1.36B | 1.08B | 797.38M | 587.92M | 478.31M | 580.15M | 493.48M | 336.50M | -2.19M | 305.68M | 241.00M | 93.28M | 136.75M | 92.15M | 126.49M | 123.33M |
| Income Before Tax Ratio | 24.50% | 21.75% | 17.70% | 17.02% | 29.36% | 25.81% | 25.92% | 24.90% | 21.53% | 27.74% | 17.98% | 13.84% | -0.10% | 15.50% | 13.85% | 5.86% | 11.58% | 10.74% | 14.88% | 14.55% |
| Income Tax Expense | 254.28M | 209.60M | 160.10M | 114.40M | 223.84M | 164.52M | 133.65M | 97.68M | 74.86M | 88.58M | 81.66M | 55.51M | 39.18M | 44.99M | 24.80M | -8.91M | 12.89M | -963.40K | 14.53M | 20.96M |
| Net Income | 1.32B | 1.12B | 785.53M | 611.97M | 1.14B | 911.77M | 664.72M | 489.54M | 403.42M | 602.93M | 411.81M | 281.00M | -41.40M | 260.59M | 216.10M | 102.11M | 123.83M | 93.12M | 111.96M | 102.37M |
| Net Income Ratio | 20.40% | 17.45% | 14.66% | 14.36% | 24.51% | 21.81% | 21.61% | 20.73% | 18.16% | 28.83% | 15.00% | 11.56% | -1.92% | 13.22% | 12.42% | 6.42% | 10.49% | 10.85% | 13.17% | 12.08% |
| EPS | 0.44 | 0.38 | 0.26 | 0.20 | 0.38 | 0.30 | 0.23 | 0.17 | 0.14 | 0.17 | 0.14 | 0.10 | -0.01 | 0.09 | 0.09 | 0.04 | 0.06 | 0.05 | 0.07 | 0.07 |
| EPS Diluted | 0.44 | 0.38 | 0.26 | 0.20 | 0.37 | 0.30 | 0.23 | 0.17 | 0.14 | 0.17 | 0.14 | 0.10 | -0.01 | 0.09 | 0.09 | 0.04 | 0.06 | 0.05 | 0.07 | 0.07 |
| Weighted Avg Shares Out | 2.98B | 2.99B | 3.02B | 3.03B | 3.03B | 3.00B | 2.84B | 2.83B | 2.92B | 2.94B | 2.93B | 2.93B | 2.93B | 2.77B | 2.44B | 2.43B | 2.30B | 1.74B | 1.27B | 1.27B |
| Weighted Avg Shares Out (Dil) | 2.98B | 2.99B | 3.03B | 3.04B | 3.05B | 3.04B | 2.91B | 2.85B | 2.92B | 2.96B | 2.94B | 2.93B | 2.93B | 2.77B | 2.46B | 2.43B | 2.30B | 1.74B | 1.27B | 1.27B |
Source: https://incomestatements.info
Category: Stock Reports